Compare Amgen, Inc. (AMGN) vs Core Scientific Inc (CORZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Core Scientific Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Core Scientific Inc trades at $23.09 (market cap $7.47B). The key difference: Amgen, Inc. is far larger — about 26.3× Core Scientific Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals.
| AMGN | CORZ | |
|---|---|---|
Market Cap | $196.12B | $7.47B |
Sector | Health | Technology |
52-Week High | $388.16 | $29.16 |
52-Week Low | $271.18 | $12.51 |
Enterprise Value | $241.41B | $8.52B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CORZ trades at $23.49, down 1.05% on the day, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue growth driven by AI colocation, yet missed EPS estimates. Strong analyst support exists with 19 buy ratings and a $34.17 consensus target, indicating 45% upside potential.
Outlook remains optimistic due to strategic pivot to AI infrastructure, though significant risks include persistent losses, high cash burn, and execution challenges in scaling data center operations amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →
